SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CYPB - Cypress BioScience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (491)2/7/1999 7:38:00 PM
From: muddphudd  Read Replies (1) of 586
 
TexasDude,

Could you post the article? What do they mean by 'modest'?

I am very concerned (as an investor) about the efficacy of the Prosorba column. One of the things that has worried me the most is the fact that rheumatologists at the same hospital I work in told me that they do not see significant effects with Prosorba, that they have concerns with the original trial design, and that they do not plan on using it! If you look at the study, they used the ACR 20 criteria. If they use the ACR 50 criteria, there is no statistically significant effect. Nonetheless, I DO believe that the column will help some people; The question is how many (%) and can CYPB generate significant revenues from that population to further develop their pipeline (Cyplex).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News